Ascendis Pharma A/S
Ascendis Pharma A/S Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- Continued steady underlying increase in patients on therapy for YORVIPATH, driving strong sequential growth expected in Q2 and beyond. - Q1 2026 operating profit was EUR 25 million with a 10% operating margin; non-IFRS operating profit was EUR 55 million, with a 22% margin.
From Ascendis Pharma A/S's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Continued steady underlying increase in patients on therapy for YORVIPATH, driving strong sequential growth expected in Q2 and beyond.
- SKYTROFA revenues expected to remain stable throughout 2026, following similar seasonal patterns as 2025.
- Early demand for YUVIWEL is encouraging, with over 60 prescriptions in less than 5 weeks post-launch, suggesting strong growth potential.
- Expansion opportunities for YORVIPATH include higher doses (up to 60 micrograms in the U.S.), geographic expansion, and label extensions to new patient groups (ages 8, 12 to 18).
- Long-term confidence due to large patient populations: 70,000 to 90,000 with chronic hypoparathyroidism in the U.S. and 5-10 times more globally.
2 more points from Ascendis Pharma A/S's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Ascendis Pharma A/S said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company emphasizes continued investment in R&D as a key component of their capital allocation strategy.
- Focus is on sustaining innovation and new product development into the 2030s and beyond.
- New chemical entities (NCEs) are being highlighted as important upcoming areas.
- Post-Q2 call, the company plans to provide more detailed guidance on outlook and capital allocation.
2 more points from Ascendis Pharma A/S's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Ascendis Pharma A/S said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has not explicitly stated a current or expected orderbook or pending orders value.
- However, they reported strong demand trends, for example:
- Over 60 prescriptions of YUVIWEL in less than 4–5 weeks since launch.
- More than 1,000 new patients prescribed YORVIPATH in Q1 2026.
- Over 6,300 patients prescribed YORVIPATH in the U.S. as of March 2026.
- Insurance approval rates for U.S. products are improving, with a cumulative approval rate approaching mid-70%.
2 more points from Ascendis Pharma A/S's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Ascendis Pharma A/S and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ascendis Pharma A/S Q2 FY26 results?
- Continued steady underlying increase in patients on therapy for YORVIPATH, driving strong sequential growth expected in Q2 and beyond. - Q1 2026 operating profit was EUR 25 million with a 10% operating margin; non-IFRS operating profit was EUR 55 million, with a 22% margin.
What is Ascendis Pharma A/S share price analysis?
Ascendis Pharma A/S currently shows a below-average growth signal. The stock trades at a P/E of 27.2 with a market cap of $14,718. Investors should review the full earnings analysis for detailed insights.
Is Ascendis Pharma A/S planning capital expenditure?
- The company emphasizes continued investment in R&D as a key component of their capital allocation strategy.
Keep Ascendis Pharma A/S on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.